- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01035268
Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella (GRATSEC)
Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella. Adipocyte Transplant for Esthetical Relapse Treatment of Breast Conservative Treatment
This is a phase III randomized multi-center study of equivalence comparing the radiological follow-up for patients benefiting from the correction of the esthetical relapse of the preservative treatment by fatty transfer compared with a simple supervision.
It is planned that 440 patients participate in this study which plans to compare 2 groups of patients: a group of patients which will benefit from the surgical treatment by transfer of fatty tissue and a group of patients under simple supervision.
follow-up consultations are planned in 10 in 45 days post-surgery then at 3 months, 6 months, 12 months and 5 years to look for the expected unwanted effects in relation with the surgery but also to estimate the impact of the fatty transfer on the rate of local and\or from a distance relapse.
During these consultations, the surgeon and the patient will also estimate the cosmetic result of the surgery thanks to a questionnaire of cosmetic evaluation and to standardized photos.
Studieöversikt
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Besançon, Frankrike, 25030
- CHU de Besancon
-
Bois-Guillaume, Frankrike, 76230
- Clinique Saint Antoine
-
Bordeaux, Frankrike, 33076
- Institut Bergonie
-
Bordeaux, Frankrike, 33076
- CHU Pellegrin
-
Chambray-Les-Tours, Frankrike, 37145
- Pole de Sante de Leonard de Vinci
-
Créteil, Frankrike, 94010
- Hôpital Henri Mondor
-
Lyon, Frankrike, 69437
- Hopital Edouard Herriot
-
Lyon, Frankrike, 69004
- Centre Hospitalier La Croix Rousse
-
Marseille, Frankrike, 13273
- Institut Paoli Calmettes
-
Marseille, Frankrike, 13005
- CHR Marseille Conception
-
Montpellier, Frankrike, 34298
- Centre Val D'Aurelle
-
Nantes, Frankrike, 44000
- Clinique Bretéché
-
Paris, Frankrike, 75010
- Hopital Saint Louis
-
Paris, Frankrike, 75005
- INSTITUT CURIE - Site Paris
-
Rennes, Frankrike, 35042
- Centre Eugène Marquis
-
Rouen, Frankrike, 76038
- Centre Henri Becquerel
-
Saint-Cloud, Frankrike, 92210
- INSTITUT CURIE - René Huguenin
-
Saint-Herblain, Frankrike, 44805
- Institut de Cancérologie de l'Ouest - Centre René Gauducheau
-
Strasbourg, Frankrike, 67091
- Hôpitaux Universitaires de Strasbourg
-
Toulouse, Frankrike, 31059
- Institut Claudius Regaud
-
Toulouse, Frankrike, 31000
- CHU Rangueil
-
Vandoeuvre-lès-Nancy, Frankrike, 54511
- Centre Alexis Vautrin
-
Villejuif, Frankrike, 94805
- Institut Gustave Roussy
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- History of breast cancer treated by conservative surgery .
- Normal inclusion radiological assessment normal (ACR1 or ACR2)
- Moderate Deformations (Type I and II of the classification of Clough).
- Delay with regard to the end of the radiotherapy superior or equal to one-year-old.
- Moderated radio-dystrophies (< Grade 2 of the score LENT/SOMA).
- Signature of the informed consent
- Patient benefiting from social security
- Patient of more than 18 years old
Exclusion Criteria:
- Abnormal radiological assessment (ACR3, ACR4 or ACR5)
- Absence of fatty excess .
- radio surgical relapses with vast fibroses of the breast (> Grade 2 of the score LENT/SOMA).
- Patient under 18 years old.
- administrative difficulties: impossibility to provide enlightened information to the patient, the refusal to sign the consent .
- pregnant women or breast feeding women
- patient under legal guardianship
- bilateral breast cancer regardless histologic type.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: surgery by fatty tissue transfer
|
It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
|
Inget ingripande: simple supervision
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Verify that the disturbances of the radiological follow-up in 1 year will not be more frequent for the patient benefiting from fatty transfer with regard to a simple surveillance.
Tidsram: 1 year
|
1 year
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Estimate the technique on the cosmetic plan : On the quality and on the stability of the result. On the satisfaction of the patient.
Tidsram: 1 year
|
1 year
|
Estimate the technique on the carcinological plan : Estimate the rate of local relapse and\or in distance. Estimate the rate of survival of the patients.
Tidsram: 1 year
|
1 year
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Ignacio GARRIDO, MD, Institut Claudius Regaud
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 08 SEIN 08
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstcancer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
Kliniska prövningar på fatty tissue transfer
-
BayerAvslutadHepatocellulärt karcinomTaiwan